Sign in
Taking peoplePhase 3

Prophylactic Anti-aRrhythmic therapy with Amiodarone in critically ill patients admitted for an out-of-hospital Cardiac Arrest with initial shockable rhythm._PARACA

Key facts

Who runs it
Centre Hospitalier De Versailles
Where
France34 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
674 people, planned
Started
23 Sept 2025
Expected to end
1 Jan 2027
Type of study
Interventional
Record updated
27 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Patient aged ≥ 18 years
  • Admitted in intensive care unit
  • Out-of-hospital cardiac arrest with shockable rhythm
  • Presumed cardiac or unknown cause
  • Delay between ROSC and screening for randomisation < 6 hours
  • Informed consent from the patient or a surrogate or deferred consent
  • Affiliated to or benefiting from a social insurance

Who cannot take part

  • Known limitations in therapy and Do Not Resuscitate-order
  • Cardiac arrest secondary to an extra-cardiac cause (suspected or confirmed)
  • History of cardiac conduction disorders, not treated by permanent pacemaker
  • Amiodarone allergy
  • Refractory ventricular arrhythmia or electrical storm
  • Need for veno-arterial extracorporeal membrane oxygenation (VA-ECMO) at admission
  • Patient with known amiodarone long –term treatment
  • Patient already included in a clinical trial (other than observational clinical trials)
  • Moribund patient due to pre-arrest history (estimated life expectancy < 3 months)
  • Pregnant or breastfeeding women
  • Indication for amiodarone decided by the physician at ICU admission
  • Foreseeable inability to obtain secure venous access for the administration of amiodarone
  • Known or suspected hyperthyroidism

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To comparatively determine if prophylactic administration of amiodarone for 72 hours in critically ill patients admitted after an OHCA with shockable rhythm, with a confirmed or a presumed cardiac cause, decreases the incidence of a composite endpoint of 30-day (starting from inclusion) all-cause mortality and/or severe in-hospital ventricular arrhythmia recurrence (ventricular fibrillation and/or ventricular tachycardia requiring intervention including re-arrest)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
27 August 2026